Metastasis is the major cause of death in cancer patients accounting for about 90% of the mortality. The detection and analysis of the hallmark of metastasis, circulating tumor cells (CTCs), have significant impact in cancer biology and clinical practice. However, the scarcity of CTCs in blood, particularly in that of colorectal cancer patients, is a serious bottleneck in the development of CTC-based precision medicine. Herein, the melt electrowriting (MEW) technology was used for reproductive fabrication of a biocompatible antibody-presenting polycaprolactone filter with tailored porous structure. It is demonstrated, for the first time, that such filter can be used not only to catch cancer cells spiked in whole blood but also to culture the cancer cells directly on site. Specifically, HT29 colon cancer cells can be captured with an efficiency of 85%, and when spiked into 4 mL of whole blood, 47% were captured on one Ø12mm filter. Furthermore, repeated capture and culture experiments have shown that as few as 20 HT29 colon cancer cells spiked into 4 mL of whole blood can be captured on the filter and within 2 weeks be expanded on site to become tumor bodies that are visible to the untrained eye. This filter allows for downstream analysis, such as flow cytometry, immunocytochemistry, Western blotting, and rt-qPCR. This technology represents a simple and cost-effective platform that potentially enables fast and efficient culture of rare CTCs from patients’ blood. This provides non-invasive alternatives for solid biopsy tumor materials for treatment screening, with great potential to realize precision medicine for cancer treatment.

转移是癌症患者的主要死亡原因，约占死亡率的90％。对转移标志，循环肿瘤细胞（CTC）的检测和分析对癌症生物学和临床实践具有重大影响。然而，血液中四氯化碳的缺乏，特别是大肠癌患者的缺乏，是基于四氯化碳的精密医学发展的严重瓶颈。本文中，熔体电写（MEW）技术用于具有定制的多孔结构的生物相容性抗体呈递聚己内酯过滤器的繁殖制造。首次证明，这种过滤器不仅可以用于捕获全血中掺入的癌细胞，而且可以直接在现场培养癌细胞。具体来说，HT29结肠癌细胞的捕获效率为85％，当掺入4 mL全血时，在一个Ø12mm过滤器上捕获了47％。此外，重复的捕获和培养实验表明，掺入4 mL全血的少至20个HT29结肠癌细胞可以在过滤器上捕获，并在2周内就地扩增变成未经训练的眼睛可见的肿瘤。该过滤器可用于下游分析，例如流式细胞仪，免疫细胞化学，蛋白质印迹和rt-qPCR。该技术代表了一个简单且具有成本效益的平台，可以潜在地实现对患者血液中稀有CTC的快速高效培养。这为实体活检肿瘤材料的治疗筛选提供了非侵入性替代方法，具有实现癌症精确治疗的巨大潜力。